Multiple indirect lines of evidence point at a cardioprotective role for enhanced bradykinin formation. In particular, the inhibition of angiotensin-converting enzyme, also known as kininase II, can protect against cardiac ischemia, putatively via accumulation of bradykinin. To address whether an increase in kinin formation is sufficient to protect against cardiac ischemia, we studied transgenic rats harboring the human tissue kallikrein gene TGR(hKLK1) under the control of the metallothionein promoter, which drives expression of the transgene in various organs including the heart. We subjected the isolated hearts from transgenic rats and their transgene negative littermates to ex vivo regional cardiac ischemia and reperfusion. During the experiment, the hearts were treated with either vehicle or the specific bradykinin type 2 receptor antagonist HOE 140 (10 -9 M). In the transgenic rats, overflow of nucleotide breakdown products upon reperfusion was significantly less (455±54 nmol/min/g in transgene negative rats vs. 270±57 nmol/min/g in the transgenic rats, P<0.05). Systolic dP/dt at the end of ischemia was significantly higher (P<0.05) in the transgenic rats than in the transgene negative controls, despite a similar reduction in total coronary flow during ischemia. These differences were abolished in the rat hearts where HOE140 was co-infused. This finding suggests that a chronic increase in tissue kallikrein can increase bradykinin levels sufficiently to protect against cardiac ischemia and that this effect is brought about by a rapid mechanism, rather than by long term structural alterations.
protective stems from the early observation that inhibitors of angiotensin-converting enzyme (ACE)-or kininase II-can protect against cardiac ischemia (1, 2) .
It has remained enigmatic why ACE inhibition protects against cardiac ischemia in isolated buffer-perfused rat hearts (1, 2) . ACE inhibitors protect against cardiac ischemia in various in vivo and ex vivo models so that they limit infarct size (3) and even may protect against reinfarction (4) . However, inhibition of angiotensin II formation cannot explain all of these beneficial effects. It is particularly difficult to reconcile the effects of ACE inhibitors in the isolated buffer-perfused heart with the finding that spontaneous generation of angiotensin I does not seem to occur in isolated buffer-perfused rat hearts (5) .
Therefore, alternative explanations have been sought to explain the effects of ACE inhibitors on ischemia. Because ACE inhibitors also prevent the degradation of kinins, it has been widely hypothesized that the effects of ACE inhibition may be explained by accumulation of bradykinin.
Schölkens et al. (6) reported in 1988 that bradykinin antagonism indeed largely abolished the protective effects of the ACE inhibitor ramipril in isolated rat and guinea pig hearts. In 1996, Liu et al. (7) reported that the ACE inhibitor ramipril reduced infarct size in an in vivo model and that this effect was abolished by the bradykinin B2-receptor antagonist HOE140. Furthermore, in this model the angiotensin II type 1 receptor blocker losartan did not attenuate infarct size. Indeed, bradykinin seems to be generated locally even in isolated buffer-perfused hearts (8) . Taken together, these studies suggest that accumulation of bradykinin may be an important mechanism by which ACE inhibitors may protect the heart against ischemic damage. However, it is not established whether increased bradykinin is sufficient to protect against cardiac ischemia. Because ACE degrades many other substrates, the studies where an ACE inhibitor is used cannot exclude that accumulation of substrates other than bradykinin may act in concert to establish the observed effects.
We set out to evaluate whether a primary increase of bradykinin (in the absence of ACE inhibition) protects against cardiac ischemia. Therefore, we used a transgenic rat model that we recently developed with a generalized overexpression of kallikrein, the enzyme that catalyzes the formation of bradykinin from kininogen. We assessed ischemic myocardial damage in these rats in the presence and absence of the specific bradykinin B2-receptor antagonist HOE140.
METHODS

Generation and breeding of transgenic rats
Transgenic rats were generated as described in a separate manuscript (9) . In brief, a 5.6-kb DNA fragment containing the entire hKLK1 gene under the control of the heavy-metal responsive mouse metallothionein (mMT1) promoter was microinjected into Sprague-Dawley (SD) rat oocytes, and the resultant founders were bred to homozygosity. The studies in this manuscript were done in the line TGR(hKLK1) also described by Silva et al. (9) . These transgenic rats are characterized by expression of the transgene in all organs, with a rank order of expression heart > kidney > brain > lung. In conscious, freely moving transgenic rats, mean arterial pressure is slightly lower with a difference of 4.4 ± 1.1 mmHg (9).
General protocol
Ischemia-reperfusion was done in male transgenic rats and their nontransgenic littermates at the age of 1 year. A total of 20 transgenic rats and 20 nontransgenic littermates were studied. In each group, 10 rat hearts were assigned to receive intracoronary HOE140 treatment (10 -9 M) during the experiment; the others received vehicle treatment (0.9% NaCl). HOE140 was started at the beginning of the experiment (i.e., before the onset of regional ischemia).
In vivo left ventricular function parameters were assessed in a separate group of normal and transgenic rats (SD, n=16, transgenic n=11).
All experiments and procedures were approved by our local animal experiment ethics committee.
In vivo left ventricular function parameters
After induction of anesthesia with ketamine (50mg/kg; Parke Davis, Germany) and xylazine 2% (5mg/kg; Medistar, Germany), the rats were intubated and mechanically ventilated (respirator, Ugo Basile (Type 7025); FMI, Germany). The thoracic cavity was opened, and the left ventral ribs were partially removed to permit access to the apex of the heart. The left ventricle was punctured by a 20-g plastic cannula, through which a 2 F Millar-tip catheter was introduced into the left ventricular cavity. The left ventricular pressure (LVP) and the heart rate (HR) signal were amplified by a DC bridge amplifier, Type 660 (Hugo Sachs, Germany). The phasic pressure signal also indicated the maximal rate of pressure rise (dP/dt max, in mmHg/s) as a measure of systolic function and contractility via transformation by a slope quotient-coupler Type 575 (Hugo Sachs). LVP and dP/dt max were all recorded on a Mark VII Linearecorder (Graphtec, Japan).
Ischemia reperfusion studies
All rats were anesthetized with ether and heparinized (500 IU kg -1 administered via the tail vein). Immediately thereafter the heart was excised and immediately arrested in icecold 0.9% NaCl (4°C). Then retrograde perfusion (60-mmHg constant pressure) of the aorta was started with a modified Tyrode buffer according to the method of Langendorff as described previously (1) . In short, the buffer was led through a 1.2-µm pore-size filter before reaching the heart. The temperature, measured in the aorta cannula tip, was kept between 38-38.5°C. Coronary flow was measured with a microprocessor, which controlled the perfusion pressure by adjusting a peristaltic perfusion pump. Left ventricular peak systolic pressure (LVP) was determined with a catheter inserted into the left ventricle that was connected to a pressure transducer. A ligature was loosely placed around the left descending coronary artery. Baseline LVP, coronary flow, positive dP/dt, and heart rate were recorded after 10 min equilibration. After the equilibration period, the hearts were kept stable for 15 min, after which the ligature was tightened for 15 min. Hereafter, the ligature was released, and the heart was reperfused for 15 min.
Assessment of nuclear breakdown products
The total overflow of the catabolites of adenosine (inosine, hypoxanthine, and xanthine) was measured in the coronary effluent at various time points during ischemia and immediately upon reperfusion. This provides a sensitive indicator of ischemic damage as we have described in previous studies (10). One-minute samples were collected before the start of ischemia (t=15), at the end of ischemia (t=30), immediately upon reperfusion (t=31), and at t = 35, 45 and 60 min. The purines were assessed by a standard HPLC determination as described previously (10).
Statistical analysis
Differences between means were evaluated by a Student's t-test, where P < 0.05 was assumed to indicate statistical significance. Significance of the effects of the transgene and/or acute co-administration of HOE140 was assessed by a two-way analysis of variance, testing for interactions between transgene status and treatment.
RESULTS
General characteristics
In the transgenic rats that overexpress kallikrein, blood pressure was slightly lower, which was not statistically significant (Table 1) . Furthermore, heart-weight to bodyweight ratio was slightly decreased, which was of borderline statistical significance. Heart rate was similar in both strains.
We assessed parameters of left ventricular function, both in vivo during anesthesia and ex-vivo in the isolated heart. This demonstrated that under both conditions there were no statistically significant differences between the SD rats and the transgenic rats (Table 2 ). It also demonstrated that although heart rate and LVP differed between the in vivo and ex vivo measurement, dP/dt was similar under both conditions (Table  2) .
Ischemia reperfusion in the isolated heart
Baseline coronary flow (ml/mg -1 ) before tightening the ligation was significantly increased in the untreated transgenic rats as compared with their untreated transgenic negative littermates (12.6±0.7 v. 10.7± 0.5; P=0.032; Fig. 1 ). This difference in baseline coronary flow was acutely abolished by co-administration of HOE140 in the perfusion buffer (Fig. 1) . Although acute treatment with HOE140 significantly decreased coronary flow in the transgenic rats, it hardly affected coronary flow in the nontransgenic littermates (Fig. 1) .
During ischemia, flow decreased to a similar extent in all groups, irrespective of transgene status, or of HOE140 administration (Fig. 1) . Post-ischemic hyperemia occurred in all four groups to a similar extent (Fig. 1) . All hearts developed reperfusion arrhythmias upon release of the ligature. The duration of reperfusion arrhythmias did not differ between the transgenic rats and their controls. Furthermore, HOE140 did not affect the duration or incidence of reperfusion arrhythmias.
However, there were differences with regard to the overflow of nucleotide breakdown products. The total amount of purines released at reperfusion was significantly less in the untreated transgenic rats, as compared with the untreated nontransgenic control littermates. HOE140 abolished this difference. HOE140 did not have an effect in control rats on the total overflow of purines (Fig. 2) .
Furthermore, there were differences with regard to the extent to which ischemia impaired systolic contractility as measured by systolic dP/dt (Fig. 3) . Systolic dP/dt clearly decreased during left ventricular ischemia. However, dP/dt decreased significantly less in the transgenic rats, a difference that was abolished by co-infusion of HOE140. Moreover, HOE140 itself seemed to have effects on cardiac contractility, irrespective of transgene status. HOE140 administration tended to decrease dP/dt before, and particularly after, ischemia, which reached statistical significance when comparing SD rats with and without HOE140 (Fig. 3) .
DISCUSSION
In this study, we addressed whether a chronic primary increase expression of kallikrein in a transgenic rat model protects against cardiac ischemia. We show that cardiac ischemia-reperfusion injury is attenuated, as demonstrated by both decreased formation of nucleotide breakdown products and attenuated impairment of systolic contractility in the ischemic hearts of transgenic rats that overexpress kallikrein. This suggests that a chronic increase in bradykinin is sufficient to protect the heart against ischemic damage and can limit infarct size. We also demonstrate that this is a result of an acute effect of bradykinin, because the B2-specific antagonist HOE140, when given acutely ex vivo, was able to completely abolish the protective effects seen in the transgenic rats. This effect of HOE140 seems specific for the transgenic rats with high kallikrein expression, because HOE140 did not alter ischemic damage in normal control rat hearts.
The importance of this finding is that for the first time it is clear that an increase in bradykinin is sufficient to protect against ischemic damage. Since the first description that ACE inhibitors protect against ischemic damage even in an isolated bufferperfused rat heart (1, 2), it has been suggested that bradykinin may be instrumental in this protection (11) . Several studies have indeed shown that HOE140 could abolish these ex vivo effects of ACE inhibitors, which substantiated a role for bradykinin. However, it has remained unclear whether an increase in bradykinin is not only necessary, but may also be sufficient to protect against cardiac ischemia.
Our study demonstrates that even the effects of a long-standing high-kallikrein expression could be acutely counteracted by HOE140 given only ex vivo, just minutes before the start of ischemia. This negates the option that long-standing effects of increased bradykinin, such as chronic lower blood pressure, slightly lower LV/body weight ratios, or possibly structural alterations would confer the protective effects of high kallikrein expression. The mechanism by which increased bradykinin protects against ischemia remains ill understood. The putative mechanisms can now be narrowed down to those that act acutely, such as ischemic preconditioning. Indeed, kinins were suggested to play a role in ischemic preconditioning (7), which underlines the rapid beneficial effects of kinins, rather than an effect that only becomes relevant after a long-term increase in kinins. In accordance, recent clinical studies also suggest an immediate protective effect of local bradykinin in patients undergoing balloon angioplasty (12) . In agreement with a rapid protective effect of bradykinin is the earlier observation that the cardioprotective effects of ACE inhibitors were also seen acutely (i.e., ACE inhibitors protected against ischemic damage even when they were only given ex vivo just minutes before the start of ischemia) (1).
We also demonstrate an increase in baseline coronary flow in the rats that overexpress kallikrein. Again, this seems to be a result of an acute vasodilatatory effect of bradykinin, rather than a structural effect because acute administration of HOE 140 abolished this difference. This is of interest, because it negates the speculation that a chronic increase in kinins may recruit vessel formation and thereby structurally increase myocardial blood flow. The increase in coronary flow also concurs with the acute increase in coronary flow seen with pretreatment with an ACE inhibitor in the same model (10).
The protection against ischemic damage in the transgenic rats was also evidenced by an attenuated impairment of systolic dP/dt. However, the data on left ventricular contractility were obtained in an ex vivo setting and not in a working heart preparation, so that this data needs to be interpreted with caution. To determine whether the values obtain in this setting are comparable to those obtained in-vivo, we compared the ex vivo obtained data to in vivo functional hemodynamics as obtained by direct cannulation of the left ventricle with a microtip catheter. This revealed that the baseline cardiac hemodynamics are comparable between the transgenic rats and their transgene negative littermates. It demonstrated that the ex vivo measurement of heart rate and left ventricular pressure differs from the in vivo values, which is probably largely a result of great differences in hemodynamics between an openchested in vivo cannulation and the unloaded ex vivo measurement. However, it also demonstrated highly comparable data with regard to dP/dt in these very differing situations (Table 2) . Therefore, this suggests that the ex vivo measured dP/dt, although still artificial, is reliable enough to indicate dynamic changes within one experiment.
Taken together, the findings on cardiac performance indicate that in the transgenic rats, increased expression of kallikrein acutely protects via bradykinin against ischemia related systolic dysfunction. Indirect evidence for an immediate effect of bradykinin on cardiac function has been reported earlier, when HOE140 counteracted the improvement of diastolic function by ACE inhibition (13) . The consequence of this finding is that interventions that acutely increase bradykinin in the heart may protect against cardiac ischemia. This would imply that acute administration of ACE inhibitors could have such effects.
In conclusion, we demonstrate for the first time that kallikrein overexpression protects against cardiac ischemia. One of the most noteworthy findings is that this protective effect of long-standing overexpression is still completely abolished by acute blockade of B2 receptors. Therefore, this study not only shows that increased bradykinin is sufficient to protect against cardiac ischemic damage, but also that this effect is a result of an acute protective mechanism against myocardial injury. To allow a separate visualization of the effects of the transgene and the effects of HOE140, two of the four groups are depicted at a time. In the upper panels A and B, the differences between transgene-negative SD rats and the transgenic rats is depicted, after vehicle treatment (A) or after HOE140 (B). In the lower panels C and D, the effects of HOE140 are depicted in the Sprague-Dawley (SD) transgene-negative littermates (C) or in the transgenic rats (D). Coronary flow is depicted as relative to left ventricular weight. Baseline coronary flow is higher in the untreated transgenic rats than in the untreated transgene-negative littermates (panel A, P=0.032). However, co-infusion with HOE140 abolished this difference (panel B, P=0.332). After occlusion of the left coronary artery, flow is reduced to a similar extent in all groups, and upon release of the ligature, reactive hyperemia and the subsequent return of coronary flow to baseline values is similar in all groups.
Figure 2.
Overflow of total purines is depicted for the four groups. Total purines clearly peak upon release of the ligature, reflecting the washout of ischemia-induced breakdown products. HOE140 itself did not affect the overflow of purines, as in the transgenenegative littermates HOE140 did not alter the level of purines (C). However, in the untreated transgenic rats, the overflow of purines was significantly reduced (A), which was abolished by co-infusion of HOE140 (B). Changes in systolic dP/dt as a measure of left ventricular function is depicted for the four groups. Systolic dP/dt clearly decreases upon the start of ischemia, and recovers after releasing the ligature. This decrease in dP/dt was significantly less in the untreated transgenic rats (A). This difference was abolished by co-infusion of HOE140 (B). HOE140 itself decreased systolic dP/dt in both transgenic and SD control rats (C, D) already before the start of ischemia, although this did not attain statistical significance in either group. None of the differences between SD rats and transgenic rats is statistically significant. In the hearts from both groups subjected to Langendorff perfusion LVP was significantly higher, and heart rate was significantly lower (* p<0.05)
as compared to the measurement in-vivo. Systolic dP/dt did not differ significantly between the two types of measurement. Data are mean±SEM
